What Is a Therapeutic Equivalent? Pharmacy Concepts for PI Cases
Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 6 min read
A therapeutic equivalent is a drug product that contains the same active ingredient, strength, dosage form, and route of administration as a reference product and produces the same clinical effect. Understanding therapeutic equivalence is essential for personal injury medication documentation.
A therapeutic equivalent is a pharmaceutical product that the FDA has determined to be equivalent to a reference (brand-name) drug in active ingredient, dosage form, strength, route of administration, quality, performance characteristics, and intended use. Two products rated as therapeutically equivalent are expected to produce the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.
- The FDA publishes therapeutic equivalence ratings in the "Orange Book" (Approved Drug Products with Therapeutic Equivalence Evaluations), using a two-letter code system
- An "AB" rating means the generic has met bioequivalence testing standards and can be substituted for the brand product
- In personal injury cases, therapeutic equivalence is relevant when pharmacies substitute generic medications for prescribed brand-name drugs
- LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages
- As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Understanding therapeutic equivalence helps attorneys and patients recognize that a generic fill is clinically identical to the brand — what matters for the case is that the right medication was dispensed, regardless of manufacturer"
The FDA Orange Book Rating System
The FDA classifies drug products using a two-letter therapeutic equivalence code. The first letter indicates the overall equivalence rating:
"A" products — the FDA considers these therapeutically equivalent to the reference product. They have no known or suspected bioequivalence problems and can be substituted with confidence.
"B" products — the FDA does not consider these therapeutically equivalent. They may have actual or potential bioequivalence problems that have not been resolved through adequate evidence.
The most common "A" ratings include:
- AB — bioequivalent based on in vivo bioequivalence testing. This is the standard generic substitution rating.
- AA — products in conventional dosage forms with no known bioequivalence problems (typically simple solutions or readily bioavailable forms).
- AP — injectable aqueous solutions.
- AT — topical products.
Therapeutic Equivalence vs. Pharmaceutical Equivalence
These terms are distinct:
Pharmaceutical equivalents contain the same active ingredient, same dosage form, same route of administration, and same strength. However, they may differ in inactive ingredients (binders, fillers, dyes) and manufacturing processes.
Therapeutic equivalents are pharmaceutical equivalents that have additionally demonstrated bioequivalence — meaning they produce the same blood levels of the active drug at the same rate and to the same extent. Therapeutic equivalents can be substituted with the expectation of producing the same clinical outcome.
Why Therapeutic Equivalence Matters in Personal Injury
In personal injury medication management, therapeutic equivalence is relevant in several contexts:
Generic substitution at the pharmacy — state pharmacy practice acts in most jurisdictions allow or require pharmacists to substitute an AB-rated generic for a prescribed brand-name product unless the prescriber writes "Dispense as Written" (DAW). When the pharmacy record shows a generic medication name, attorneys should understand that the generic is clinically equivalent to the brand.
Insurance formulary management — health insurers and PBMs use therapeutic equivalence to justify coverage decisions. A formulary may cover only the generic version of a drug, requiring the patient to accept the AB-rated generic or pay significantly more for the brand.
Medication record clarity — when reviewing a patient's medication history, the same drug may appear under different names (brand vs. generic, or generics from different manufacturers). Understanding therapeutic equivalence helps attorneys and case managers recognize that these are the same medication, not different treatments.
Pharmacy lien documentation — when LienScripts fills prescriptions under a lien arrangement, the dispensed product (brand or generic) is documented precisely. According to James Wong, PharmD, founder of LienScripts, "Every prescription fill in the lien record includes the exact drug product dispensed, the NDC number, and the manufacturer. This level of detail ensures the medication record is unambiguous for legal purposes."
Narrow Therapeutic Index Drugs: The Exception
Some medications have a narrow therapeutic index (NTI), meaning small differences in blood levels can produce significant clinical differences. For NTI drugs — including warfarin, levothyroxine, certain anti-seizure medications, and immunosuppressants — generic substitution may be clinically appropriate but requires closer monitoring. Prescribers may write "DAW" for NTI drugs to ensure the patient receives the same manufacturer's product at each fill.
In personal injury cases involving traumatic brain injury (anti-seizure medications) or DVT prophylaxis (warfarin after surgical recovery), NTI drug management may appear in the medication record and deserves specific attention.
Therapeutic Alternatives vs. Therapeutic Equivalents
A therapeutic alternative is a different chemical entity that produces similar therapeutic outcomes but is not bioequivalent. For example, naproxen and ibuprofen are therapeutic alternatives — both are NSAIDs that reduce inflammation, but they are different molecules with different pharmacokinetics.
This distinction matters because insurance step therapy protocols often substitute therapeutic alternatives, not therapeutic equivalents. The substitution of a different drug (therapeutic alternative) is a clinical decision that should be made by the prescriber, not mandated by the insurer. A pharmacy lien avoids this issue entirely because there is no insurance formulary involved.
Related Resources
- What Is Bioequivalence?
- What Is a Compounded Medication?
- Generic vs. Brand Name Injury Medications
- What Is Step Therapy in Personal Injury?
Frequently Asked Questions
Is a generic medication the same as the brand-name version?
An AB-rated generic is considered therapeutically equivalent to the brand — it contains the same active ingredient, same strength, same dosage form, and has demonstrated bioequivalence through FDA-required testing. The generic may differ in inactive ingredients (fillers, dyes) but is expected to produce the same clinical effect. For personal injury medication records, a generic fill is clinically equivalent to the brand.
What is the FDA Orange Book?
The FDA Orange Book — formally titled 'Approved Drug Products with Therapeutic Equivalence Evaluations' — is a database that lists all FDA-approved drug products and their therapeutic equivalence ratings. An AB rating indicates the generic has met bioequivalence testing requirements and can be substituted for the brand. Pharmacists, insurers, and clinicians reference the Orange Book for substitution decisions.
Does it matter if a pharmacy lien fills a generic instead of a brand-name drug?
In most cases, an AB-rated generic produces the same clinical outcome as the brand-name product and is an appropriate fill. The pharmacy lien record through LienScripts documents the exact product dispensed — including manufacturer and NDC number — ensuring complete transparency. For narrow therapeutic index drugs, the prescriber may specify DAW to require a specific product.